company background image
BMMJ

Body and Mind OTCPK:BMMJ Stock Report

Last Price

US$0.079

Market Cap

US$8.0m

7D

-9.5%

1Y

-83.4%

Updated

26 Sep, 2022

Data

Company Financials
BMMJ fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health4/6
Dividends0/6

BMMJ Stock Overview

Body and Mind Inc. cultivates, processes, distributes, and retails medical and recreational cannabis in Nevada, California, Arkansas, Ohio, and Michigan in the United States.

Body and Mind Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Body and Mind
Historical stock prices
Current Share PriceUS$0.079
52 Week HighUS$0.59
52 Week LowUS$0.065
Beta2.4
1 Month Change-13.76%
3 Month Change-23.71%
1 Year Change-83.39%
3 Year Change-89.08%
5 Year Change-64.09%
Change since IPO-99.99%

Recent News & Updates

Shareholder Returns

BMMJUS PharmaceuticalsUS Market
7D-9.5%-1.9%-5.2%
1Y-83.4%2.9%-23.0%

Return vs Industry: BMMJ underperformed the US Pharmaceuticals industry which returned 2.9% over the past year.

Return vs Market: BMMJ underperformed the US Market which returned -23% over the past year.

Price Volatility

Is BMMJ's price volatile compared to industry and market?
BMMJ volatility
BMMJ Average Weekly Movement11.5%
Pharmaceuticals Industry Average Movement11.6%
Market Average Movement6.9%
10% most volatile stocks in US Market15.8%
10% least volatile stocks in US Market2.8%

Stable Share Price: BMMJ is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: BMMJ's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
1998101Mike Millshttps://www.bodyandmind.com

Body and Mind Inc. cultivates, processes, distributes, and retails medical and recreational cannabis in Nevada, California, Arkansas, Ohio, and Michigan in the United States. The company offers packaged and grinded flower buds; concentrates; Gpen vaporizers; distillate oil cartridges; and distillate infused edible products. It also produces and sells medical and adultuse recreational marijuana products, such as cannabis flower, oil, extracts, and edibles under the Body and Mind brand name.

Body and Mind Fundamentals Summary

How do Body and Mind's earnings and revenue compare to its market cap?
BMMJ fundamental statistics
Market CapUS$7.96m
Earnings (TTM)-US$6.12m
Revenue (TTM)US$30.43m

0.3x

P/S Ratio

-1.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
BMMJ income statement (TTM)
RevenueUS$30.43m
Cost of RevenueUS$21.50m
Gross ProfitUS$8.93m
Other ExpensesUS$15.04m
Earnings-US$6.12m

Last Reported Earnings

Apr 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-0.054
Gross Margin29.34%
Net Profit Margin-20.10%
Debt/Equity Ratio24.7%

How did BMMJ perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is BMMJ undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BMMJ?

Other financial metrics that can be useful for relative valuation.

BMMJ key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue0.6x
Enterprise Value/EBITDA19x
PEG Ration/a

Price to Sales Ratio vs Peers

How does BMMJ's PS Ratio compare to its peers?

BMMJ PS Ratio vs Peers
The above table shows the PS ratio for BMMJ vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average0.8x
NBRV Nabriva Therapeutics
0.2x34.5%US$5.8m
STMH Stem Holdings
0.2xn/aUS$4.9m
AYTU Aytu BioPharma
0.1x9.3%US$11.6m
ACAN AmeriCann
2.6xn/aUS$7.3m
BMMJ Body and Mind
0.3xn/aUS$8.0m

Price-To-Sales vs Peers: BMMJ is good value based on its Price-To-Sales Ratio (0.3x) compared to the peer average (0.8x).


Price to Earnings Ratio vs Industry

How does BMMJ's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

Price-To-Sales vs Industry: BMMJ is good value based on its Price-To-Sales Ratio (0.3x) compared to the US Pharmaceuticals industry average (2.8x)


Price to Sales Ratio vs Fair Ratio

What is BMMJ's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BMMJ PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio0.3x
Fair PS Ration/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate BMMJ's Price-To-Sales Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of BMMJ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate BMMJ's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate BMMJ's fair value for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies

Future Growth

How is Body and Mind forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

Future Growth Score

0/6

Future Growth Score 0/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


10.0%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Body and Mind has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Discover growth companies

  • Examine Body and Mind's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  • While we do not consider unaudited financials to be a reliable enough to include in our analysis, you can access them on the OTC Markets Website. If you are looking for more of a qualitative research into the company, you can access Body and Mind's filings and announcements here.

Past Performance

How has Body and Mind performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-28.3%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: BMMJ is currently unprofitable.

Growing Profit Margin: BMMJ is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: BMMJ is unprofitable, and losses have increased over the past 5 years at a rate of 28.3% per year.

Accelerating Growth: Unable to compare BMMJ's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: BMMJ is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (5%).


Return on Equity

High ROE: BMMJ has a negative Return on Equity (-18.69%), as it is currently unprofitable.


Discover strong past performing companies

Financial Health

How is Body and Mind's financial position?

Financial Health Score

4/6

Financial Health Score 4/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: BMMJ's short term assets ($11.9M) exceed its short term liabilities ($9.4M).

Long Term Liabilities: BMMJ's short term assets ($11.9M) do not cover its long term liabilities ($13.3M).


Debt to Equity History and Analysis

Debt Level: BMMJ's net debt to equity ratio (12.4%) is considered satisfactory.

Reducing Debt: Insufficient data to determine if BMMJ's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BMMJ has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: BMMJ has sufficient cash runway for 1.4 years if free cash flow continues to reduce at historical rates of 8.7% each year.


Discover healthy companies

Dividend

What is Body and Mind current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate BMMJ's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate BMMJ's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if BMMJ's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if BMMJ's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as BMMJ has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.1yrs

Average management tenure


CEO

Mike Mills (53 yo)

3.08yrs

Tenure

US$336,095

Compensation

Mr. Michael Mills, also known as Mike, serves as Chief Executive Officer at Body and Mind Inc. since April 30, 2020 and its President since August 21, 2019. Mr. Mills served as the Chairman of the Board of...


CEO Compensation Analysis

Mike Mills's Compensation vs Body and Mind Earnings
How has Mike Mills's remuneration changed compared to Body and Mind's earnings?
DateTotal Comp.SalaryCompany Earnings
Apr 30 2022n/an/a

-US$6m

Jan 31 2022n/an/a

-US$4m

Oct 31 2021n/an/a

-US$2m

Jul 31 2021US$336kUS$163k

-US$2m

Apr 30 2021n/an/a

-US$3m

Jan 31 2021n/an/a

-US$4m

Oct 31 2020n/an/a

-US$4m

Jul 31 2020US$336kUS$155k

-US$4m

Compensation vs Market: Mike's total compensation ($USD336.09K) is below average for companies of similar size in the US market ($USD780.01K).

Compensation vs Earnings: Mike's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: BMMJ's management team is considered experienced (3.1 years average tenure).


Board Members

Experienced Board: BMMJ's board of directors are considered experienced (5.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

OTCPK:BMMJ Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
04 May 22BuyUS$3,000Stephen HoffmanIndividual20,000US$0.15
22 Mar 22BuyUS$20,756Michael MillsIndividual109,000US$0.19
22 Mar 22BuyUS$20,756Michael MillsIndividual109,000US$0.19
03 Feb 22BuyUS$6,250Stephen HoffmanIndividual25,000US$0.25
03 Feb 22BuyUS$6,250Stephen HoffmanIndividual25,000US$0.25
11 Jan 22BuyUS$4,758Dong Hyun ShimIndividual16,667US$0.29
23 Dec 21BuyUS$6,010Michael MillsIndividual20,000US$0.30
22 Dec 21BuyUS$5,500Stephen HoffmanIndividual20,000US$0.28

Ownership Breakdown

What is the ownership structure of BMMJ?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders764,4600.7%
Private Companies5,741,2955.1%
General Public107,162,85894.3%

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.8%.


Top Shareholders

Top 7 shareholders own 5.72% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
3.76%
SW Fort Apache, LLC
4,278,761$338.0k0%no data
1.29%
Ti Nevada, Llc
1,462,534$115.5k0%no data
0.22%
Robert Hasman
250,000$19.8k0%no data
0.18%
Michael Mills
206,000$16.3k0%no data
0.12%
Dong Hyun Shim
138,460$10.9k0%no data
0.088%
Darren Tindale
100,000$7.9k0%no data
0.062%
Stephen Hoffman
70,000$5.5k40%no data

Company Information

Body and Mind Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: Body and Mind Inc.
  • Ticker: BMMJ
  • Exchange: OTCPK
  • Founded: 1998
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$7.957m
  • Shares outstanding: 113.67m
  • Website: https://www.bodyandmind.com

Number of Employees


Location

  • Body and Mind Inc.
  • 750 – 1095 West Pender Street
  • Vancouver
  • British Columbia
  • V6E 2M6
  • Canada


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
BMMJOTCPK (Pink Sheets LLC)YesCommon StockUSUSDNov 2005
BAMMCNSX (Canadian National Stock Exchange)YesCommon StockCACADNov 2005

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/26 00:00
End of Day Share Price2022/09/26 00:00
Earnings2022/04/30
Annual Earnings2021/07/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.